Skip to content
MarketScale
‹ Back to IndustriesSciences

Hyundai Motors Acquires Boston Dynamics: How Can Robotics Scale Car Manufacturing?

Hyundai Motors has acquired Boston Dynamics for over $1 billion, signaling a significant move towards increased use of robotics in car manufacturing. The investment is seen as a step towards integrating advanced automation and enhancing research and development for new vehicles. Experts believe combining robotics with human efforts could lead to improved manufacturing efficiency.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · AutomationAutomotiveAutomotive ManufacturingBoston Dynamics
Share
Hyundai Motors Acquires Boston Dynamics: How Can Robotics Scale Car Manufacturing?

Key takeaways

01

Hyundai Motors invested more than $1 billion in acquiring Boston Dynamics to advance robotics in automotive manufacturing.

02

Experts believe the integration of robotics is aimed at enhancing research and development efforts rather than immediate large-scale changes.

03

A symbiotic relationship between humans and robotic systems could lead to significant efficiency gains in manufacturing.

Automotive industry giant Hyundai Motors made waves recently, acquiring noted robotics lab Boston Dynamics for more than $1 billion. That’s a hefty investment – but what does it really represent?

To find out, Voice of B2B Daniel Litwin sat down with Konstantin Maslennikov, CEO and Founder of HereYouGo, which is working to empower anyone to rent part of a fleet of autonomous vehicles as we collectively move toward a self-driving future.

Even though Hyundai’s aggressive move represents a big step toward increased automation, Maslennikov said the process might be more glacier than avalanche.

“You cannot change everything in one day,” he said. “I think it’s more for research and development purposes, mostly. … Maybe for new vehicles.”

The duo explored where Hyundai might get the most out of its investment in Boston Dynamics, how robotic solutions are getting smarter and preparing to scale up, the role of automation in self-driving vehicle manufacturing at scale, and more.

While many companies are working toward that future, it’s still easier to use humans than artificial intelligence in some applications.

“It’s going to be some kind of symbiosis,” Maslennikov said. “Because, if people work with computers, the efficiency just grows very fast. … But we are not there yet, especially with AI enablement. Like, robots making robots? Robots making self-driving cars? We are not there yet.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Daniel Litwin
Daniel Litwin

Voice of B2B at MarketScale

MarketScale

Daniel Litwin is a communications specialist focused on B2B industries, providing insights and commentary across a range of sectors. He works with MarketScale to deliver valuable insights in engineering, construction, and technology fields.

KM
Konstantin Maslennikov

CEO and Founder

HereYouGo

Konstantin Maslennikov is the CEO and Founder of HereYouGo, a company focused on advancing autonomous vehicle technology and enabling rental models for fleet sharing. He is a thought leader in self-driving technology and automation.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512